Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein.
Medical countermeasures to prevent or treat smallpox are needed due to the potential use of poxviruses as biological weapons. Safety concerns with the currently available smallpox vaccine indicate a need for research on alternative poxvirus vaccine strategies. Molecular vaccines involving the use of proteins and/or genes and recombinant antibodies are among the strategies under current investigation. The poxvirus L1 protein, encoded by the L1R open reading frame, is the target of neutralizing antibodies and has been successfully used as a component of both protein subunit and DNA vaccines. L1-specific monoclonal antibodies (e.g., mouse monoclonal antibody mAb-7D11, mAb-10F5) with potent neutralizing activity bind L1 in a conformation-specific manner. This suggests that proper folding of the L1 protein used in molecular vaccines will affect the production of neutralizing antibodies and protection. Here, we co-crystallized the Fab fragment of mAb-7D11 with the L1 protein. The crystal structure of the complex between Fab-7D11 and L1 reveals the basis for the conformation-specific binding as recognition of a discontinuous epitope containing two loops that are held together by a disulfide bond. The structure of this important conformational epitope of L1 will contribute to the development of molecular poxvirus vaccines and also provides a novel target for anti-poxvirus drugs. In addition, the sequence and structure of Fab-7D11 will contribute to the development of L1-targeted immunotherapeutics.
Su
Hua-Poo
HP
Structural Biology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12441 Parklawn Drive, Rockville, MD 20852, USA.
Golden
Joseph W
JW
Gittis
Apostolos G
AG
Hooper
Jay W
JW
Garboczi
David N
DN
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000378:metabolism; D000914:Antibodies, Viral / Q000737:chemistry / Q000378:metabolism; D019556:COS Cells; D002460:Cell Line; D002522:Chlorocebus aethiops; D003460:Crystallization; D004268:DNA-Binding Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D000939:Epitopes / Q000737:chemistry; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000378:metabolism; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011212:Poxviridae / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D011487:Protein Conformation; D014616:Vaccinia virus / Q000276:immunology*; D014709:Vero Cells; D014758:Viral Core Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D004268:DNA-Binding Proteins; D000939:Epitopes; C109350:I1 protein, vaccinia virus; D007140:Immunoglobulin Fab Fragments; D014758:Viral Core Proteins
Methods. 2005 May;36(1):25-34
15848072
Virology. 1999 Feb 1;254(1):71-80
9927575
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1882-7
16436502
Virology. 2005 Oct 10;341(1):91-101
16061267
Methods Enzymol. 1997;276:307-26
27754618
Acta Crystallogr D Biol Crystallogr. 2005 Jun;61(Pt 6):750-4
15930633
Vaccine. 2007 Feb 26;25(10):1814-23
17240007
J Virol. 2005 Sep;79(18):11724-33
16140750
J Mol Biol. 1993 Dec 20;234(4):946-50
8263940
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18572-7
16339313
Acta Crystallogr D Biol Crystallogr. 2005 Apr;61(Pt 4):458-64
15805601
J Mol Biol. 1971 Feb 14;55(3):379-400
5551392
Virology. 2006 Nov 25;355(2):164-74
16919703
Virology. 1999 May 25;258(1):189-200
10329580
Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11178-92
15249657
Virology. 2005 Oct 10;341(1):59-71
16083934
Virology. 2003 Feb 1;306(1):181-95
12620810
Virology. 2000 Jan 20;266(2):329-39
10639319
J Hyg (Lond). 1970 Jun;68(2):197-210
4988047
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
15299926
J Virol. 2004 Oct;78(19):10230-7
15367588
J Biol Chem. 1993 Apr 5;268(10):7585-93
8463289
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6667-72
11983854
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4240-5
15761054
Biochemistry. 2006 Feb 21;45(7):2085-93
16475797
Protein Sci. 2006 Feb;15(2):343-51
16434746
J Virol. 2005 Aug;79(15):9458-69
16014909
Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9
2025413
J Virol. 1994 Oct;68(10):6401-10
8083978
Virology. 2006 Jan 5;344(1):48-54
16364735
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4152-7
15753319
Annu Rev Biochem. 1990;59:439-73
2197980
J Immunol. 1995 Apr 15;154(8):3975-84
7706736
J Virol. 2004 May;78(9):4433-43
15078924
Virol J. 2005 Dec 09;2:91
16336686
JAMA. 1999 Jun 9;281(22):2127-37
10367824
J Virol. 2005 Nov;79(21):13454-62
16227266
Virology. 1995 Aug 1;211(1):53-63
7645236
Proc Natl Acad Sci U S A. 1997 May 13;94(10):5018-23
9144182
Clin Med Res. 2003 Apr;1(2):87-92
15931293
J Immunol. 2006 Aug 15;177(4):2552-64
16888017
FASEB J. 1995 Jan;9(1):133-9
7821752
Virology. 1994 Aug 1;202(2):834-43
8030246
Vaccine. 2007 Jan 26;25(7):1214-24
17098336
Virology. 1996 Jun 15;220(2):491-4
8661400